These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16426997)

  • 1. Calcium channels as therapeutic targets in neuropathic pain.
    Yaksh TL
    J Pain; 2006 Jan; 7(1 Suppl 1):S13-30. PubMed ID: 16426997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium channels and mechanisms of neuropathic pain.
    Devor M
    J Pain; 2006 Jan; 7(1 Suppl 1):S3-S12. PubMed ID: 16426998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voltage-dependent calcium channels.
    Lacinová L
    Gen Physiol Biophys; 2005 Jun; 24 Suppl 1():1-78. PubMed ID: 16096350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion channel targets and treatment efficacy in neuropathic pain.
    Markman JD; Dworkin RH
    J Pain; 2006 Jan; 7(1 Suppl 1):S38-47. PubMed ID: 16427000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathic pain: mechanisms and treatments.
    Ro LS; Chang KH
    Chang Gung Med J; 2005 Sep; 28(9):597-605. PubMed ID: 16323550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging targets to treat neuropathic pain.
    Butera JA
    J Med Chem; 2007 May; 50(11):2543-6. PubMed ID: 17489576
    [No Abstract]   [Full Text] [Related]  

  • 7. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
    Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
    J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules targeting sodium and calcium channels for neuropathic pain.
    Bear B; Asgian J; Termin A; Zimmermann N
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):543-61. PubMed ID: 19562650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinociceptive effect of different types of calcium channel inhibitors and the distribution of various calcium channel alpha 1 subunits in the dorsal horn of spinal cord in mice.
    Murakami M; Nakagawasai O; Suzuki T; Mobarakeh II; Sakurada Y; Murata A; Yamadera F; Miyoshi I; Yanai K; Tan-No K; Sasano H; Tadano T; Iijima T
    Brain Res; 2004 Oct; 1024(1-2):122-9. PubMed ID: 15451373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Ca2+ channels to treat pain: T-type versus N-type.
    Altier C; Zamponi GW
    Trends Pharmacol Sci; 2004 Sep; 25(9):465-70. PubMed ID: 15559248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating basic research on sodium channels in human neuropathic pain.
    Attal N; Bouhassira D
    J Pain; 2006 Jan; 7(1 Suppl 1):S31-7. PubMed ID: 16426999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voltage-dependent calcium channels--beyond dihydropyridine antagonists.
    Snutch TP; Sutton KG; Zamponi GW
    Curr Opin Pharmacol; 2001 Feb; 1(1):11-6. PubMed ID: 11712528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voltage-gated sodium channels: therapeutic targets for pain.
    Dib-Hajj SD; Black JA; Waxman SG
    Pain Med; 2009 Oct; 10(7):1260-9. PubMed ID: 19818036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cav2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain.
    Matthews EA; Bee LA; Stephens GJ; Dickenson AH
    Eur J Neurosci; 2007 Jun; 25(12):3561-9. PubMed ID: 17610575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurobiology of neuropathic pain: mode of action of anticonvulsants.
    Dickenson AH; Matthews EA; Suzuki R
    Eur J Pain; 2002; 6 Suppl A():51-60. PubMed ID: 11888242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kv7 (KCNQ) channel modulators and neuropathic pain.
    Munro G; Dalby-Brown W
    J Med Chem; 2007 May; 50(11):2576-82. PubMed ID: 17489574
    [No Abstract]   [Full Text] [Related]  

  • 19. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain.
    Winquist RJ; Pan JQ; Gribkoff VK
    Biochem Pharmacol; 2005 Aug; 70(4):489-99. PubMed ID: 15950195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presynaptic calcium channels: structure, regulators, and blockers.
    Kisilevsky AE; Zamponi GW
    Handb Exp Pharmacol; 2008; (184):45-75. PubMed ID: 18064411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.